Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224755 · ClinicalTrials.gov registry record · NA
MOMENTUM 3 IDE Clinical Study Protocol
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 1,028
- Enrollment target
NCT02224755 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,028 participants.
The verdict
NCT02224755, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,028 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the safety and effectiveness of the HM3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
Interventions
- DEVICE HeartMate 3 LVAS
- DEVICE HeartMate II LVAS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,028 participants |
| Start Date | 2014-09-02 |
| Est. Completion | 2019-03-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02224755
The ClinicalTrials.gov registry entry for NCT02224755 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,028 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HeartMate 3 LVAS is the first listed.
NCT02224755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02224755 about?
NCT02224755 is a clinical study titled "MOMENTUM 3 IDE Clinical Study Protocol". The objective of the study is to evaluate the safety and effectiveness of the HM3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
What is the current status of trial NCT02224755?
This trial is currently completed. It is a NA study. The enrollment target is 1,028 participants. The study started on 2014-09-02. Estimated completion is 2019-03-26.
What interventions are being tested in trial NCT02224755?
The interventions under investigation include: HeartMate 3 LVAS (DEVICE), HeartMate II LVAS (DEVICE).
Who is sponsoring clinical trial NCT02224755?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.